Atlas of Genetics and Cytogenetics in Oncology and Haematology


Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

t(14;17)(q32;q21) IGH/IGF2BP1

Written2014-10Guangyu Gu, Sarah South
Genetics Associates, Inc. Nashville, TN ggu@geneticsassociates.com (GG); Department of Pathology, University of Utah; ARUP Institute for Clinical, Experimental Pathology, ARUP Laboratories, Salt Lake City, UT Sarah.south@aruplab.com (SS)

Abstract IGH rearrangements are a common chromosomal abnormality seen in lymphoproliferative disorders, including ALL. Numerous translocation partners of IGH gene have been identified. Here we report a B-ALL case with a t(14;17)(q32;q21) IGH/IGF2BP1.

Keywords IGH partner, t(14;17)(q32;q21), IGF2BP1, acute B lymphoblastic leukemia

(Note : for Links provided by Atlas : click)

Identity

ICD-Topo C420,C421,C424 BLOOD, BONE MARROW, & HEMATOPOIETIC SYS
ICD-Morpho 9811/3 B lymphoblastic leukaemia/lymphoma, NOS
Atlas_Id 1706
 
  t(14;17)(q32;q21) G- Banding

Clinics and Pathology

Disease B-cell acute lymphoblastic leukemia (ALL)
Phenotype / cell stem origin CD10+, CD19+, CD38+, cytoplastic CD22+ ALL
Epidemiology Only one case, a 16 year old boy (Gu et al., 2014)
Clinics Severe pancytopenia and an elevated lactate dehydrogenase (1048U/L); WBC was 2.7 X 10 9 with 20% blasts; no central nervous system involvement.

Cytogenetics

Cytogenetics Morphological An additional copy of the derivative 14 was found

Genes involved and Proteins

Gene NameIGH (Immunoglobulin Heavy)
Location 14q32.33
Gene NameIGF2BP1 (insulin-like growth factor 2 mRNA binding protein 1)
Location 17q21.32
Protein IGF2BP1 is a member of Insulin-like growth factor 2 mRNA-binding protein family; pro-oncogenic RNA-binding; post-transcriptional regulation of gene expression (Bell et al., 2013; Lederer et al., 2014).

Result of the chromosomal anomaly

Hybrid gene
Description likely head-to-head fusion of IGF2BP1 with the IGH locus.
  
Fusion Protein
Oncogenesis Overexpression of the IGF2BP1 gene.
  

To be noted

Additional cases are needed to delineate the epidemiology of this rare entity:
you are welcome to submit a paper to our new Case Report section.

Bibliography

Insulin-like growth factor 2 mRNA-binding proteins (IGF2BPs): post-transcriptional drivers of cancer progression? Cell Mol Life Sci
Bell JL, Wächter K, Mühleck B, Pazaitis N, Köhn M, Lederer M, Hüttelmaier S
2013 Aug;70(15):2657-75 doi: 10
PMID 23069990
 
IGF2BP1: a novel IGH translocation partner in B acute lymphoblastic leukemia
Gu G, Sederberg MC, Drachenberg MR, South ST
Cancer Genet 2014 Jul-Aug;207(7-8):332-4
PMID 25195122
 
The role of the oncofetal IGF2 mRNA-binding protein 3 (IGF2BP3) in cancer
Lederer M, Bley N, Schleifer C, Hüttelmaier S
Semin Cancer Biol 2014 Dec;29:3-12
PMID 25068994
 

Citation

This paper should be referenced as such :
Guangyu Gu, Sarah South
t(14;17)(q32;q21) IGH/IGF2BP1
Atlas Genet Cytogenet Oncol Haematol. 2015;19(8):541-542.
Free journal version : [ pdf ]   [ DOI ]
On line version : http://AtlasGeneticsOncology.org/Anomalies/t1417q32q21IGH-IGF2BP1ID1706.html


Translocations implicated (Data extracted from papers in the Atlas)

 t(14;17)(q32;q21) IGH/IGF2BP1

External links

IGH (14q32.33) IGF2BP1 (17q21.32)

Mitelman databaset(14;17)(q32;q21) [Case List]    t(14;17)(q32;q21) [Association List] Mitelman database (CGAP - NCBI)
arrayMapTopo ( C42) Morph ( 9811/3) - arrayMap (UZH-SIB Zurich)  [auto + random 100 samples .. if exist ]   [tabulated segments]
 
Mitelman databaseIGH/IGF2BP1 [MCList]  IGH (14q32.33) IGF2BP1 (17q21.32)
 
Disease databaset(14;17)(q32;q21) IGH/IGF2BP1
REVIEW articlesautomatic search in PubMed
Last year articlesautomatic search in PubMed
All articlesautomatic search in PubMed


© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Tue Nov 21 15:10:12 CET 2017


Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

For comments and suggestions or contributions, please contact us

jlhuret@AtlasGeneticsOncology.org.